Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major retinal edema markets reached a value of US$ 5.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 13.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.84% during 2024-2034.

The retinal edema market has been comprehensively analyzed in IMARC's new report titled "Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinal edema refers to the accumulation of fluid in the layers of the retina, the light-sensitive tissue lining the back of the eye. This condition is often a result of various underlying issues, such as diabetic retinopathy, macular degeneration, retinal vein occlusion, or inflammatory diseases. The symptoms of the illness can vary but commonly include blurred or distorted vision, decreased visual acuity, and the perception of floating spots or floaters. Individuals suffering from the ailment might also experience changes in color perception and difficulty with low-light vision. Since these symptoms can overlap with other eye conditions, an accurate diagnosis is crucial. The diagnosis of retinal edema typically involves a comprehensive eye examination, which may include visual acuity tests and optical coherence tomography (OCT) to visualize retinal layers and fluid accumulation. A healthcare provider will also conduct fluorescein angiography to evaluate blood flow within the retina and detect any abnormalities.

The increasing cases of diabetic retinopathy, macular degeneration, and retinal vein occlusion, which can cause microvascular abnormalities and disruptions in the retinal barrier, are primarily driving the retinal edema market. In addition to this, the inflating utilization of effective therapeutic approaches, including anti-VEGF agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc., to effectively manage the condition and mitigate further visual impairment, is creating a positive outlook for the market. Moreover, the widespread adoption of advanced retinal imaging techniques, that enable precise visualization of retinal structures and facilitate early detection of edema is also bolstering the market growth. Apart from this, the rising usage of personalized medicine, wherein treatment strategies are tailored to individual patient profiles, including their genetic predispositions and response to therapies, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vitreoretinal surgery, owing to its numerous advantages, such as enhancing patient's quality of life, reducing macular thickness, and preventing associated complications, is also augmenting the market growth. Furthermore, the escalating demand for regenerative therapies, encompassing stem cell-based approaches and gene editing techniques, to help in addressing the root causes of the illness, is expected to drive the retinal edema market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinal edema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for retinal edema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinal edema market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinal edema market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinal edema market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current retinal edema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the retinal edema market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the retinal edema market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the retinal edema market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of retinal edema across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinal edema by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinal edema by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with retinal edema across the seven major markets?
What is the size of the retinal edema patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of retinal edema?
What will be the growth rate of patients across the seven major markets?

Retinal Edema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for retinal edema drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinal edema market?
What are the key regulatory events related to the retinal edema market?
What is the structure of clinical trial landscape by status related to the retinal edema market?
What is the structure of clinical trial landscape by phase related to the retinal edema market?
What is the structure of clinical trial landscape by route of administration related to the retinal edema market?